2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 815

Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
Abstract Number: 1874

Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Abstract Number: 2134

Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica
Abstract Number: 2431

Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers
Abstract Number: 750

Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort
Abstract Number: 575

Facet Joint Ankylosis on Whole Spine Low-Dose CT in Radiographic Axial Spondyloarthritis
Abstract Number: 1132

Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Abstract Number: 1584

Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort
Abstract Number: 2866

Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Abstract Number: 1197

Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice
Abstract Number: 618

Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis
Abstract Number: 1618

Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity
Abstract Number: 2330

Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis
Abstract Number: 2448

Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Abstract Number: 2560

Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].